BioRestorative Therapies Inc

BRTX13 Dec 2024
Healthcare
$1.46
0.00 (-0.34%)
Lowest Today
$1.41
Highest Today
$1.5
Today’s Open
$1.46
Prev. Close
$1.46
52 Week High
$3.67
52 Week Low
$1.03
To Invest in BioRestorative Therapies Inc

BioRestorative Therapies Inc

Healthcare
BRTX13 Dec 2024
0.00 (-0.34%)
1M
3M
6M
1Y
5Y
Low
$1.41
Day’s Range
High
$1.5
1.41
52 Week Low
$1.03
52-Week Range
52 Week High
$3.67
1.03
1 Day
-
1 Week
-
1 month return
-
3 month return
-16.94%
6 month return
-24.61%
1 Year return
-22.63%
3 Years return
-71.67%
5 Years return
-
10 Years return
-
Institutional Holdings
Geode Capital Management, LLC
0.8
StoneX Group Inc
0.72
Wealth Alliance, LLC
0.58
Fidelity Extended Market Index
0.43
Vanguard Group Inc
0.3
Vanguard Institutional Extnd Mkt Idx Tr
0.3
State Street Corp
0.3

Market Status

Fundamentals
Market Cap
10.1 mln
PB Ratio
1.02
PE Ratio
0
Enterprise Value
-2.86 mln
Total Assets
12.61 mln
Volume

Company Financials

Fund house & investment objective

Company Information
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.
Organisation
BioRestorative Therapies Inc
Employees
11
Industry
Biotechnology
CEO
Mr. Lance  Alstodt
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step